ACE and COVID-19: SARS-CoV-2 binding to the endothelium of target cells, including blood vessels, is accelerated by the ACE-2 receptors, in which those target cells upregulated by diabetes and hypertension treated with ACE inhibitors or angiotensin II type-I receptor blockers (ARBs), leading to the exacerbation of infection, with COVID-19 increasing the risk of mortality [77].